Grace Therapeutics (GRCE) Receivables - Accured (2019 - 2023)

Grace Therapeutics has disclosed Receivables - Accured across 3 years of filings, most recently posting $143000.0 for Q1 2023.

• In Q1 2023, Receivables - Accured rose 101.41% year-over-year to $143000.0; the TTM figure through Mar 2023 stood at $143000.0 (up 101.41% YoY), while the FY2023 annual figure was $143000.0, up 101.41% from the prior year.
• Receivables - Accured came in at $143000.0 for Q1 2023 at Grace Therapeutics, up from $71000.0 in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $143000.0 in Q1 2023 to a low of $60155.1 in Q1 2019.
• Average Receivables - Accured over 3 years is $91385.0, with a median of $71000.0 recorded in 2022.
• The largest YoY upside for Receivables - Accured was 101.41% in 2023 against a maximum downside of 101.41% in 2023.
• Over 3 years, Receivables - Accured stood at $60155.1 in 2019, then increased by 18.03% to $71000.0 in 2022, then surged by 101.41% to $143000.0 in 2023.
• Per Business Quant data, the three most recent Receivables - Accured figures were $143000.0 in Q1 2023, $71000.0 in Q1 2022, and $60155.1 in Q1 2019.